pharma

Uncategorized

Delhi High Court Restrains Dr. Reddy’s, OneSource in Novo Nordisk’s Weight Loss Drug Patent Dispute

/

In a significant legal development, the Delhi High Court has issued an interim injunction restraining Indian pharmaceutical major Dr. Reddy’s Laboratories and OneSource Nutra from manufacturing, selling, or distributing generic versions of a weight loss drug patented by Danish pharmaceutical company Novo Nordisk. The dispute centers around semaglutide, the active ingredient in Novo Nordisk’s blockbuster […]

Uncategorized

Biofrontera Inc. Secures Extended Patent Protection for Ameluz® and Completes Patient Enrollment in Phase 2b Acne Study

/

Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological treatments, has announced two significant milestones: the extension of U.S. patent protection for its flagship product, Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, and the completion of patient enrollment in its Phase 2b clinical trial evaluating Ameluz® for the treatment of moderate to severe acne

Uncategorized

Delaware Court Upholds Acadia’s Patent Rights, Secures Protection for Nuplazid Formulation

/

In a significant legal victory for Acadia Pharmaceuticals Inc., a Delaware district court has ruled in favor of the company’s arguments concerning patent infringement and validity, providing crucial protection for its flagship product, Nuplazid. The ruling reinforces Acadia’s intellectual property rights and ensures continued exclusivity for the formulation of the drug, which is widely used

Uncategorized

Delhi High Court Clarifies Patent Law Standards in Landmark Ruling on Section 3(d) of the Indian Patents Act, 1970

/

In a landmark judgment, the Delhi High Court has provided critical clarity on the interpretation and application of Section 3(d) of the Indian Patents Act, 1970, particularly in cases concerning pharmaceutical innovations. The decision, rendered in the matter of Ischemix LLC v. The Controller of Patents, emphasizes the standards of patentability and the admissibility of

Uncategorized

Nobel Prize Winners Convince Court to Revive CRISPR Patent Dispute

/

In a significant legal development with profound implications for the future of genetic engineering, a U.S. federal appeals court has agreed to revisit a high-stakes patent battle over CRISPR-Cas9 gene-editing technology. This decision follows a petition spearheaded by Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier, who are seeking to reclaim intellectual property rights over

Uncategorized

Indian Pharma Stocks Tumble Amid Trump’s Drug Price Cut Order: Industry Braces for Patent Clampdown

/

In a significant development that sent shockwaves across global pharmaceutical markets, U.S. President Donald Trump signed an executive order aimed at drastically reducing prescription drug prices in the United States. The move has triggered a sharp decline in Indian pharmaceutical stocks, raising concerns about the future of generic drug exports and the potential tightening of

Uncategorized

Clearmind Medicine Secures European Patent Publication for Psychedelic-Based Cocaine Addiction Therapy

/

Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotechnology firm focused on the development of next-generation psychedelic-based treatments, has officially announced the publication of a European patent application for its novel cocaine addiction therapy. The patent, filed with the European Patent Office (EPO) under number EP 4531826, represents a critical milestone in the company’s

Uncategorized

Navigating the Genomics Revolution: The Evolving Role of Intellectual Property Protection

/

More than two decades after the landmark announcement of the Human Genome Project’s completion in 2003, the field of genomics is undergoing a profound transformation. What began as a focus on decoding linear DNA sequences has expanded into a multidisciplinary understanding of the genome’s structural and functional complexity. This includes insights into protein folding, post-translational

Uncategorized

ABVC BioPharma Secures Japanese Patent for Botanical Depression Drug ABV-1504, Strengthens Global IP Portfolio

/

In a significant boost to its intellectual property portfolio, U.S.-based clinical-stage biopharmaceutical company ABVC BioPharma has received a key patent grant in Japan for its novel antidepressant candidate, ABV-1504. The newly issued patent secures exclusive rights in Japan for the innovative botanical-based treatment through 2040, reinforcing the company’s commitment to addressing global mental health challenges

Scroll to Top